Taysha Faces Stock Delisting, Scraps $75M Durham Manufacturing Facility

Taysha Gene Therapies faces potential delisting of its shares—the latest in a series of setbacks that include scrapping a $75-million manufacturing facility in Durham, NC.

Related Keywords

North Carolina ,United States ,Dallas ,Texas ,Seanp Nolan ,Jackk Allen ,Kamran Alam ,Job Development Investment Grant ,Carolina Community Colleges ,Carolina Economic Investment Committee ,European Commission Ec Orphan Drug ,Nasdaq ,Healthcare Products Regulatory Agency ,Taysha Gene Therapies ,Nasdaq Global Select Market ,Nasdaq Capital Market ,Investigational New Drug ,Clinical Trial Application ,Responsive Auto Regulatory Element ,Orphan Drug ,Rare Pediatric Disease ,European Commission ,Board Chairman Sean ,Motor Function Measure ,Astellas Gene Therapy ,North Carolina Economic Investment Committee ,North Carolina Community Colleges ,